Pharmafile Logo
Pharmafocus logo
Advanced Search

GSK

Showing 15 posts of 760 posts found.

GSK expands apprenticeship programme

March 13, 2012
Manufacturing and Production, Research and Development GSK, Hayes, R&D, manufacturing

GlaxoSmithKline has expanded its apprenticeship programme with the creation of positions spanning manufacturing, IT, and R&D.  The multi-disciplinary scheme is …

News
Antonio Tajani

Can Europe really agree to speed up pricing and reimbursement?

March 6, 2012
Sales and Marketing Europe, European Commission, GSK, Sir Andrew Witty, pricing and reimbursement

The European Commission has called for faster decisions to allow new medicines to enter the market faster.The Commission says the …

Feature
gsk_hq_logo

GSK collaborates with Dundee on neglected diseases

March 6, 2012
Research and Development, Sales and Marketing Africa, Dundee, GSK, Gates, Wellcome

GlaxoSmithKline has teamed up with Dundee University and the Wellcome Trust to develop new drugs for neglected diseases.  Healthcare charity …

News
GSK picture

GSK recalls Novartis’ blood pressure drug

February 28, 2012
Manufacturing and Production DynaCirc CR, GSK, Novartis

GlaxoSmithKline is the latest company to be affected by manufacturing glitches at Novartis’ troubled facility in Lincoln, Nebraska, having been …

News

Witty hits out at ‘systematic delays’ to medicines

February 27, 2012
Sales and Marketing Europe, GSK, NICE, austerity

 GlaxoSmithKline’s chief executive says Europe’s drug budget cuts are undermining the industry and not addressing the biggest cost pressure in …

News
Tyverb picture

GSK pulls Tyverb extension in Europe

February 17, 2012
Sales and Marketing GSK, Herceptin, Tyverb, Xeloda

GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …

News

Emerging markets no haven from HTA, says NICE

February 15, 2012
Andrew Witty, GSK, NICE, NICE International

The head of NICE says pharma will face health technology assessment barriers in every country – including fast-growing developing markets. …

News
Herceptin and Tyverb image

NICE cannot recommend breast cancer drugs

February 14, 2012
Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb

NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …

News
GSK picture

GSK posts strong underlying sales growth

February 8, 2012
Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix

GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead.  The UK firm saw 4% …

News

James Murdoch steps down from GSK board

January 27, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, James Murdoch

GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will …

Appointment

Underwhelming results for GSK’s Relovair

January 10, 2012
Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …

News

GSK faces fine over Argentina clinical trial

January 6, 2012
Research and Development, Sales and Marketing Argentina, GSK, Vaccine, deaths, emerging markets

A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …

News

GSK’s Andrew Witty knighted

January 3, 2012
Sales and Marketing Andrew Witty, GSK

GlaxoSmithKline chief executive Andrew Witty and former ABPI director general Richard Barker were among the recipients in the 2012 New …

News
GSK picture

GSK sells off over-the-counter brands

December 22, 2011
Sales and Marketing GSK, OTC

GlaxoSmithKline has offloaded a number of OTC consumer health brands in North America for £426 million in cash.  Flagged up …

News
The SEC

GSK’s Stiefel accused of shares fraud

December 13, 2011
Sales and Marketing GSK, SEC, Stiefel, fraud

The US financial regulator has charged a subsidiary of GlaxoSmithKline with defrauding staff by buying back shares from them at …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025